Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05929079

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Status
Active Not Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
1,000 (estimated)
Sponsor
Eli Lilly and Company · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Conditions

Interventions

TypeNameDescription
DRUGRetatrutideAdministered SC
DRUGPlaceboAdministered SC

Timeline

Start date
2023-07-11
Primary completion
2026-05-01
Completion
2026-05-01
First posted
2023-07-03
Last updated
2026-04-13

Locations

98 sites across 8 countries: United States, Argentina, Australia, Brazil, India, Mexico, Romania, Spain

Regulatory

Source: ClinicalTrials.gov record NCT05929079. Inclusion in this directory is not an endorsement.